Array Biopharma Inc (NASDAQ:ARRY) Director Lunsen Gil J. Van sold 21,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $16.76, for a total transaction of $360,340.00. Following the completion of the sale, the director now owns 26,297 shares of the company’s stock, valued at approximately $440,737.72. The sale was disclosed in a filing with the SEC, which is accessible through this link.
ARRY stock traded up $0.04 during trading on Wednesday, reaching $16.80. 2,161,004 shares of the company’s stock traded hands, compared to its average volume of 4,041,659. The firm has a market cap of $3,413.55, a price-to-earnings ratio of -21.82 and a beta of 1.80. The company has a current ratio of 6.17, a quick ratio of 6.17 and a debt-to-equity ratio of 0.39. Array Biopharma Inc has a 1 year low of $6.73 and a 1 year high of $18.78.
Array Biopharma (NASDAQ:ARRY) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Array Biopharma had a negative net margin of 98.51% and a negative return on equity of 107.79%. The firm had revenue of $42.21 million for the quarter, compared to analyst estimates of $26.81 million. During the same quarter in the prior year, the business earned ($0.14) EPS. The company’s revenue for the quarter was down 5.2% compared to the same quarter last year. research analysts expect that Array Biopharma Inc will post -0.88 EPS for the current fiscal year.
Several equities research analysts recently commented on ARRY shares. Leerink Swann upgraded shares of Array Biopharma from a “market perform” rating to an “outperform” rating in a research report on Monday, January 22nd. BidaskClub lowered shares of Array Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday. SunTrust Banks reiterated a “buy” rating and issued a $20.00 price objective on shares of Array Biopharma in a research note on Tuesday, February 6th. Jefferies Group upped their price objective on shares of Array Biopharma to $13.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Finally, Stifel Nicolaus upped their price objective on shares of Array Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $16.43.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Array Biopharma Inc (ARRY) Director Sells 21,500 Shares of Stock” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://stocknewstimes.com/2018/03/21/insider-selling-array-biopharma-inc-arry-director-sells-21500-shares-of-stock.html.
About Array Biopharma
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.